Nosopharm is an innovative biotechnology company specialized in the research and development of new molecules to combat antimicrobial resistance (AMR).
Location: France, Auvergne-Rhône-Alpes, Lyon
Total raised: $5.74M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Auriga Par... | auriga.vc |
| 27.03.2021 | Elaia Part... | elaia.com |
Funding Rounds 3
Mentions in press and media 4
| Date | Title | Description |
| 15.07.2022 | Former Spark exec to lead a gene therapy upstart of his own; Big Pharma marketing vet named CEO of Swiss biotech | Joseph La Barge → Dave Greenwald’s days as acting CEO of Apertura Gene Therapy are over as Joseph La Barge steps in to lead the biotech, which just launched in April. Peer Review had been wondering about La Barge’s next landing sp... |
| 12.02.2018 | Nosopharm Receives €1M Loan from Bpifrance | Nosopharm, a Lyon, France-based company dedicated to the research and development of new anti-infective drugs, received €1m ($1.2M) in funding. Bpifrance provided the funding in the form of an interest-free loan. The company will use the pr... |
| 29.03.2017 | Term Sheet — Wednesday, March 29 | IPOS ARE COOL AGAIN For that reason, I’ve always thought the official end of the unicorn era would happen when the biggest, most valuable, most high profile and most quintessential billion-dollar startups, Airbnb and Uber, finally went publ... |
| 28.03.2017 | Nosopharm Raises €2.4M in Funding | Nosopharm, a Lyon, France-based biotechnology company specialized in the research and development of new antimicrobial molecules, raised €2.4m in funding. Backers included Auriga Partners, Kreaxi and Alto Invest, which joined Nosopharm’s lo... |